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Abstract Late-onset Alzheimer’s disease (LOAD) is a
devastating neurodegenerative disease with no effective
treatment or cure. In addition to APOE, recent large gen-
ome-wide association studies have identified variation in
over 20 loci that contribute to disease risk: CR1, BIN1,
INPP5D, MEF2C, TREM2, CD2AP, HLA-DRB1/HLA-
DRB5, EPHA1, NME8, ZCWPW1, CLU, PTK2B, PICALM,
SORL1, CELF1, MS4A4/MS4A6E, SLC24A4/RIN3,FER-
MT2, CD33, ABCA7, CASS4. In addition, rare variants
associated with LOAD have also been identified in APP,
TREM2 and PLD3 genes. Previous research has identified
inflammatory response, lipid metabolism and homeostasis,
and endocytosis as the likely modes through which these
gene products participate in Alzheimer’s disease. Despite
the clustering of these genes across a few common path-
ways, many of their roles in disease pathogenesis have yet
to be determined. In this review, we examine both general
and postulated disease functions of these genes and con-
sider a comprehensive view of their potential roles in
LOAD risk.
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Introduction
Alzheimer’s disease (AD) is the sixth leading cause of death in
the US. Healthcare costs in 2013 alone surpassed $200 billion
(USD), and this figure is estimated to be over 1 trillion dollars
by 2050 [www.alz.org]. AD is characterized by two patho-
logical hallmarks in affected areas of the brain, extracellular
deposition of senile plaques and intracellular occurrence of
neurofibrillary tangles (NFTs), produced by abnormal aggre-
gation of amyloid beta (Ab) and hyperphosphorylation of tau,
respectively. These plaques and tangles interfere with calcium
signaling and synaptic transmission, induce a constant state of
inflammation in the brain and ultimately lead to neuronal
death. Patients with AD often initially present with mild
cognitive impairment (MCI), which progresses to more severe
memory loss and eventually loss of autonomy.
Alzheimer’s disease is a complex and multifactorial
neurodegenerative disease and a leading cause of dementia
among elderly people. However, a small number of indi-
viduals develop AD at a younger age, and because of this
variation in age at onset, the disease is classified into early
(\60 years age) and late (C60 years age) onset forms.
Early onset Alzheimer’s disease (EOAD) accounts for only
1–2 % of all AD cases, and it usually follows an autosomal
dominant inheritance pattern where mutations in a single
gene can cause the disease. To date, mutations in three
genes, including amyloid precursor protein (APP), prese-
nilin (PS)-1 and PS-2, have been linked to EOAD [1–4].
Late-onset Alzheimer’s disease (LOAD) is much more
common and far more complex than EOAD with the possible
involvement of multiple genes and gene-gene and gene-
environment interactions. Until 2009, APOE was the only
established susceptibility marker for LOAD that accounts for
*25 of the estimated heritability of *80 % [5]. This indi-
cates the involvement of additional genetic factors that can
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modify the risk of LOAD. In order to identify the remaining
genes for LOAD, efforts were focused on conducting gen-
ome-wide association studies (GWAS) because this
approach is hypothesis free and conceptually would identify
all known and unknown genes. However, with the exception
of the APOE region, no other significant associations were
replicated in earlier GWAS, indicating that the effect sizes of
the remaining LOAD genes are small, and an exceptionally
large number of cases and controls are required to identify
additional genes. Since 2009, five large GWAS and a meta-
analysis have identified significant associations of LOAD
with SNPs in 20 additional loci, including CLU, CR1, PI-
CALM, BIN1, ABCA7, MS4A4, EPHA1, CD2AP CD33,
INPP5D, MEF2C, HLA-DRB1/HLA-DRB5, NME8,
ZCWPW1, PTK2B, SORL1, CELF1,SLC24A4/RIN3,FER-
MT2 and CASS4 [6•, 7•, 8•, 9•, 10•, 11••].
Generally, these genes fall into at least one of three
pathways–inflammatory, lipid metabolism and endocytosis–
all of which have been suggested to play some role in disease.
In addition to these genes where common variants are
associated with disease risk, recent studies have identified
rare variants in APP [12•], triggering receptor expressed on
myeloid cells 2 (TREM2) [13•, 14•] and phospholipase D3
(PLD3) [15•] that also confer protection or risk against
LOAD. Taken together, these findings produce a list of 24
genes/loci (Table 1), spread across the genome and loosely
falling into the three common pathways, which mediate risk
for LOAD. Below, we summarize the biology of each gene,
postulate potential pathological mechanisms based upon
their shared functions and regulatory networks, and suggest
knowledge gaps that future studies may aim to fill.
APOE (Apolipoprotein E)
The association between the APOE genotype and AD risk
is the strongest and best replicated association for any AD
risk locus where the APOE*4 is a risk allele and APOE*2
is a protective allele. Its association with LOAD risk was
determined prior to and validated with genome-wide
association studies. Some of the most attractive theories for
the role of APOE in AD pathogenesis involve its roles in
inflammatory response, oxidative stress and lipid levels
[16]. Interestingly, research has shown that both the
APOE*2 and APOE*4 alleles increase the risk of cerebral
amyloid angiopathy (CAA) by encouraging accumulation
of Ab in the cerebral vasculature [17].
Identification of LOAD Genes by Genome-wide
Association Studies
In addition to the established association of APOE, recent
GWAS have identified 20 genes/loci for LOAD. Below, we
briefly discuss the known functions of the newly identified
genes that might be relevant to AD biology. Since the
GWAS approach generally identifies a genomic region
associated with the disease and not necessarily the actual
gene when there are multiple genes in a region, some of
these genes should be considered provisional until con-
firmed by more in-depth functional tools.
CR1 (Complement Component (3b/4b) Receptor 1)
CR1 is a major player in the immune system. It serves as a B
cell receptor for fragments of complement components C3
and C4 and is involved in factor-I mediated cleavage of C3,
and thus regulates complement activation [18, 19]. The exact
relationship between CR1 function and LOAD is still unclear
[20, 21]. Evidence for a role in brain vasculature as a means
to mediate LOAD risk has been provided by Holton et al.
[22], who were able to detect low CR1 expression in white
matter and cerebellum. Individuals with the genotype pattern
PICALM-GG, CR1-GG, APOE*4 had decreased episodic
memory, an endophenotype of LOAD, regardless of their
affection status, providing further evidence of CR1’s role in
LOAD risk [23].


























a Rare variants in these genes are associated with LOAD risk
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BIN1 (Bridging Integrator 1)
BIN1 is a tumor suppressor gene that has been shown to be
involved in a number of cancers, including hepatocellular
carcinoma [24], melanoma [25], astrocytoma [26] and breast
cancer [27]. Its known role in endocytosis [28] coupled with
its association with LOAD makes it an attractive candidate
gene for AD. In one study of sporadic AD, BIN1 protein
levels were significantly lower in tissues from cases than
from those of age-matched controls and neither overex-
pression nor knockdown of BIN1 affected APP processing in
SH-SY5Y cells [29]. This study, which found no effect of
BIN1 on tau pathology, differs from another by Chapuis et al.
[30], which found BIN1 was increased in AD cases com-
pared to controls and that the Drosophila ortholog to BIN1,
Amph, mediates Tau-induced neurotoxicity. The role of
BIN1 in LOAD pathogenesis is still unclear and has been
reviewed extensively by Tan et al. [31].
INPP5D (Inositol Polyphosphate-5-Phosphatase,
145 kDa, aka SHIP1)
INPP5D plays a role in a number of inflammatory
responses in addition to its regulation of cytokine signaling
and inhibition of the PI3K-driven oncogenic pathway [32,
33]. Differential expression for this gene has been observed
between classical Hodgkin’s lymphoma (cHL) cells and
nodular lymphocyte predominant HL (nLPHL) cells, with
the Hodgkin Reed-Sternberg cells of cHL showing
decreased expression [34]. Furthermore, its expression has
been shown to inhibit proliferation of acute myeloid leu-
kemia cells [32]. Jickling et al. [35] have linked an increase
in blood INPP5D with an increased risk of hemorrhagic
transformation (HT) in ischemic stroke patients. HT is
associated with increased blood-brain barrier permeability
and thus may share some molecular mechanisms with AD.
Of note is the binding of INPP5D with the product of
another LOAD risk gene, CD2AP, in plasmacytoid den-
dritic cells (pDCs). This complex controls degradation of
IgE receptor FceRIc [36]. As we discuss later in this
review, some IgE receptors are members of the MS4A gene
superfamily that has been associated with LOAD risk,
indicating this complex and related pathways might be of
importance to AD pathogenesis.
MEF2C (Myocyte Enhancer Factor 2C)
Previously, MEF2C mutations have been correlated with
distinct phenotypes, specifically that of del5q14 syndrome,
which is similar to Rett syndrome and characterized by
seizures, severe mental retardations and stereotypical
movements [37, 38]. Sakai et al. [39] reported the first case
of del5q14 syndrome in a Japanese adolescent male who
exhibited a neuroendocrine phenotype and hypothalamic
defects. Interestingly, the Drosophila ortholog of MEF2C,
Mef2, has been shown to affect circadian behaviors and
neuronal remodeling [40]. Since a number of AD patients
experience disturbances in their circadian rhythms [41], it
is possible that the association of MEF2C is reflective of
this secondary phenotype of AD rather than pathogenesis
itself.
CD2AP (CD2-Associated Protein)
First identified as an adaptor protein with three Src-
homology 3 (SH3) domains, CD2AP binds and clusters
CD2 to facilitate junction formation between T cells and
antigen-presenting cells [42]. Its role in endocytosis has
been described, and its complex with cortactin links it to
the cytoskeleton and vesicle movement [43]. This function
makes CD2AP a prime candidate for modulating Ab
clearance. Increased susceptibility to neuritic plaque bur-
den has been linked to CD2AP variation [44]. CD2AP
behaves similarly to CIN85 (aka SH3KBP1) [43], the
homologs of which have been identified as suppressors of
Ab toxicity in yeast and C. elegans [45]. Similarly, another
study in Drosophila found that loss of the fly ortholog of
CD2AP and CIN85, cindr, increased tau neurotoxicity in
transgenic flies, further suggesting CD2AP normally
functions in a protective role against AD risk [46].
HLA-DRB1/HLA-DRB5 (Major Histocompatibility
Complex, Class II, DR Beta 1/Major Histocompatibility
Complex, Class II, DR Beta 5)
The HLA-DRB1/HLA-DRB5 locus is a member of the
major histocompatibility complex, a highly polymorphic
region located on chromosome 6 that is responsible for
numerous immune responses [47]. GWA studies have
associated this locus with both multiple sclerosis [48] and
another proteinopathy, Parkinson’s disease (PD) [49, 50].
Remarkably, knockout of MHCII in mice protects against
a-synuclein-induced neurodegeneration, which is charac-
teristic of PD [51]. While Parkinson’s and Alzheimer’s are
two distinctly different diseases, both are characterized by
neurodegeneration resulting from abnormal protein aggre-
gation. Given the association of this locus with LOAD and
the demonstration that MHCII signaling activates microg-
lia in Parkinson’s [51], HLA-DRB1/HLA-DRB5 may have a
similar role in inflammatory responses that contribute to
both pathologies.
EPHA1 (EPH Receptor A1)
The EPHA1 receptor is a member of protein tyrosine
receptors. There is high affinity for the receptor with its
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membrane-bound ligand, ephrin-A1. The interaction
between EPHA receptors and ephrins is thought to play a
role in synapse formation and development [52] and to
regulate T cell interactions through integrin pathway [53].
Expression of EPHA1 occurs in lymphocytes and epithelial
cells and is downregulated in lipopolysaccaharide (LPS)
fever-induced inflammation in rats [54]. A study of MCI
individuals compared to healthy controls identified an
association between Ab deposition and EPHA1 expression,
with the C allele of rs11767557 being associated with
decreased risk of being Ab-positive. This association was
only found in cognitively normal individuals, not those
with MCI [55]. Overexpression of EPHA1 also has been
reported to produce more aggressive tumors in ovarian
cancer [56].
NME8 (NME/NM23 Family Member 8)
Defects in NME8 (aka TXNDC3) have been associated with
primary ciliary dyskinesia [57], and variation in this gene has
been linked to increased bone mineral density and knee
osteoarthritis risk [58, 59]. Work in mice has shown that
deletion of the thioredoxin domains in sperm increases their
age-related susceptibility to oxidative stress-induced phe-
notypes [60]. Literature on this gene is limited and indicates
expression is primarily restricted to testis and respiratory
epithelial cells [60, 61]. However, if expression of NME8
was observed in the brain, the association between NME8
and AD risk could be explained by variation that modifies its
antioxidant action and subsequently alters the level of
oxidative stress. Alternatively, variation in NME8 could
serve as an eQTL (expression quantitative trait loci) for other
gene(s) whose expression is directly relevant to AD risk.
ZCWPW1 (Zinc Finger, CW Type with PWWP
Domain 1)
To date, only one paper has been published on ZCWPW1.
He et al. [62] used solution NMR spectroscopy in the first
and only determination of the 3D structure of ZCWPW1.
This protein contains zf-CW domain, which has been
identified in a number of other proteins responsible for
chromatin remodeling and methylation states. The PWWP
domain is also present in ZCWPW1 and, similar to the zf-
CW domain, has been described in epigenetic regulations,
indicating ZCWPW1 as a histone modification reader [62].
Recently, a variant in ZCWPW1 (rs1476679) associated
with LOAD risk was also found to have functional rele-
vance (RegulomeDB score: 1f), as it serves as an eQTL for
GATS, PILRB and TRIM4 and affects binding of CTCF and
RFX3 [Rosenthal, unpublished data].
CLU (Clusterin)
CLU, also referred to as apolipoprotein J (APOJ), has been
implicated in the formation of complexes that can cross the
blood-brain barrier [63]. It is one of the primary chaperones
for removal of Ab from the brain [64]. AD patients have
increased levels of CLU in the cortex and hippocampus
[65, 66], so a link between increased levels of CLU and AD
risk [67] is both expected and observed. Related to this,
Thambisetty et al. [68] found an association between
increased plasma clusterin and hippocampal atrophy, as
well as disease severity and progression, suggesting its
potential utility as a biomarker. In contrast, other studies
show that the minor allele of the associated SNP, CLU/
rs11136000, is associated with increased CLU expression
but decreased AD risk, further complicating the relation-
ship between CLU and Alzheimer’s disease [6•, 7•, 69, 70].
One possibility proposed by Ling et al. [69] is that for the
increase in CLU expression to reduce risk, it must occur
over the lifespan, prior to disease onset. In addition to its
role in neurodegeneration, CLU expression affects che-
motherapy resistance and severity of some cancers, which
may be indicative of an inflammatory mechanism of action
in AD, in addition to lipid trafficking [71–74]. Clusterin’s
role in AD pathogenesis has been reviewed in depth by
Nuutinen [64].
PTK2B (Protein Tyrosine Kinase 2 Beta)
The PTK2B gene is located on chromosome 8 near the
CLU gene. We originally reported that PTK2B was a
potential new risk gene for AD, as we found multiple
significant signals (albeit not genome-wide significant)
in the PTK2B gene [75]. This observation has now been
confirmed by the meta-analysis where PTK2B has been
identified as a genome-wide significant locus for LOAD
[11••]. PTK2B, also called PYK2, is a member of the
focal adhesion kinase (FAK) family, a non-receptor
protein tyrosine kinase family [76]. It responds to a
number of stimuli and is subsequently activated by these
stimuli through a combination of autophosphorylation
and phosphorylation by Src-family kinases [77]. One
such stimulus for PTK2B activation is changes in intra-
cellular calcium levels, which are disrupted in AD brains
[76, 78]. PTK2B indirectly regulates N-methyl-D-aspar-
tate receptor (NMDAR) activity through src kinases [79,
80]. Work in mice suggests that loss of protein tyrosine
phosphatase alpha (PTP-a), a regulator of PTK2B, can
cause defects in NMDAR processes, including memory
[81].
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MS4A4A/MS4A6E (Membrane-Spanning 4-Domains,
Subfamily A, Member 4A/Membrane-Spanning
4-Domains, Subfamily A, Member 6E)
Perhaps the most interesting AD risk locus is the MS4A
region located on chromosome 11. Despite its continued
replication in multiple GWAS and original characterization
over a decade ago, little else has been determined about
this gene family [82, 83]. Members of the MS4A family of
proteins have four transmembrane domains and are
diversely expressed [82, 83]. Similarities between the
structure and expression of mouse and human HTm4
(MS4A3), another member of the MS4A family, have been
demonstrated. Of interest is the expression of HTm4 in the
developing central nervous system of mice [84]. Expres-
sion of MS4A6A has been shown to correlate with Braak
tangle and Braak plaque scores in AD patients, as was the
minor allele MS4A6E/rs670139 [85]. Allen et al. [70] have
identified variations in proxies of the genome-wide sig-
nificant SNP rs670139 that increase MS4A4A’s expression
in the brain and subsequently increase disease risk. Given
the consistent replication of these loci with AD risk, it is
essential that this gene family be studied with more func-
tional techniques to assess its role in both normal and
disease states.
PICALM (Phosphatidylinositol Binding Clathrin
Assembly Protein)
APP trafficking as well as Ab clearance, specifically via
clathrin-mediated endocytosis (CME), is one of the pro-
posed pathways for affecting LOAD risk. Work in yeast
and C. elegans has shown homologs of PICALM to be
suppressors of Ab toxicity [45]. More recently, Ando et al.
[86] identified a link between PICALM and characteristic
tau pathology of AD brains, specifically co-localization of
PICALM with tau in NFTs, but not with pre-tangles or
extracellular ghost tangles. Alternative splicing of PICALM
yields three isoforms, and post-mortem studies of brain
samples revealed a decrease in the levels of full-length
PICALM and an increase in the shorter species in cases,
indicating abnormal proteolysis of PICALM may affect Ab
clearance although no interaction between PICALM and
Ab was observed.
SORL1 [Sortilin-Related Receptor, L(DLR class)
A Repeats Containing]
Nearly a decade ago, Scherzer et al. [87] identified a link
between decreased SORL1 (LR11) expression and AD.
Microarray analysis of lymphoblast DNA showed a clear
downregulation of SORL1 expression in AD patients, and
immunohistochemistry of AD brains exhibited decreased
staining of pyramidal neurons and lowered protein levels in
the frontal cortex. Additionally, single-site and haplotype
association of SORL1 with risk of amnestic mild cognitive
impairment (aMCI), a common precursor to AD, has been
reported in the Han Chinese [88]. Glerup et al. [89] have
demonstrated SORL1 as an endocytic modulator of glial-
derived neurotrophic factor (GDNF) and its related recep-
tor, GFRa1.
CELF1 (CUGBP, Elav-like Family Member 1)
CELF1 is largely implicated in myotonic dystrophy type I
(DMI) because of its interaction with DMPK [90, 91].
However, Kim et al. [92] have shown that elimination of
CELF1 in transgenic mice with induced RNA toxicity does
not completely alleviate features of DMI. CELF1 has also
been associated with certain types of cancer. For example,
Talwar et al. [93] have observed overexpression of CELF1
in oral squamous cancer cells results in a reduction of
proapoptotic mRNA transcripts that ultimately leads to cell
proliferation. The fly homolog of CELF1, aret, has been
shown to mediate tau toxicity [46]. Recently, we have
identified eight variants in linkage disequilibrium with the
reported CELF1/rs10838725 that have suggestive func-
tional relevance (RegulomeDB score: 1f) and are eQTLs
for C1QTNF4. These data suggest that CELF1 may be
acting in conjunction with or serving as a proxy for other
genes in this region that mediate AD risk [Rosenthal,
unpublished data].
SLC24A4/RIN3 (Solute Carrier Family 24 (Sodium/
Potassium/Calcium Exchanger), Member 4/Ras
and Rab Interactor 3)
SLC24A4 is a solute carrier that has been associated with
pigmentation traits in European populations [94, 95]. Since
SLC24A4 is involved in iris development, it may also be
involved in neuronal development and thus contribute to
AD risk [96]. Two variants in this gene have been identi-
fied in Pakistani families with amelogenesis imperfecta
(AI), and Slc24a4 knockout mice have severe enamel
defects, indicating a role for this solute carrier in amelo-
genesis [97]. Perhaps of most relevance to AD is the
association of this gene with blood pressure in African
Americans as AD may be influenced by vascular disease
[98].
FERMT2 (Fermitin Family Member 2)
FERMT2 (aka kindlin-2, KIND2) is a member of the
Fermitin family of proteins, which are involved in cell–
matrix adhesion complexes. FERMT2 can stimulate
genomic instability, which ultimately facilitates breast
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cancer progression, and it also has been identified as a
binding partner for KIND1, mutations in which are
responsible for Kindler syndrome [99, 100]. Shulman et al.
[46] independently validated the recent association of
FERMT2 with LOAD risk after performing a gene screen
and in vivo studies in Drosophila melanogaster. Their
work in flies shows altered expression of both FERMT2
and CELF1 homologs modulates Tau neurotoxicity as
measured by a retinal phenotype and suggests biological
relevance for these associations.
ABCA7 [ATP-Binding Cassette, Sub-family
A (ABC1), Member 7]
ABCA7 is a member of the ATP-binding cassette genes
that are responsible for lipid transport, a particularly
important function in the central nervous system [101].
Kim et al. [102–104] performed a number of mouse studies
concerning the expression and function of ABCA7. Loss of
ABCA7 is not embryonic lethal and does not produce any
clear irregularities in young mice, which is consistent with
the late age at onset of AD. Their work has demonstrated
that knockout of ABCA7 does not affect cholesterol efflux
by macrophages, nor is it sufficient to compensate when
function of homologous lipid transporter, ABCA1, is lost.
ABCA7 expression is highest in the hippocampus, one of
the earliest affected regions in the brains of AD patients,
and microglia, the cells responsible for cerebral inflam-
matory response [102, 103]. ABCA7 also participates in
macrophage uptake of Ab, and ablation of ABCA7 results
in increased levels of insoluble Ab [104]. ABCA7 also has
been shown to mediate APP processing [105]. It remains to
be seen whether the action of ABCA7 in AD is through its
interaction with APOE and lipid metabolism, its function
as an immune system molecule or a combination of both.
ABCA7 also has been associated with age at onset of AD
[85]. A GWAS in African Americans found an effect size
similar to APOE for ABCA7/rs115550680 (OR 2.31,
p = 5.5 9 10-47, OR 1.79, p = 2.21 9 10-9, respec-
tively), highlighting the diversity of genetic effects on
different genetic backgrounds [106].
CD33 (CD33 Molecule)
CD33 belongs to a class of immune cell surface receptors
called sialic acid-binding immunoglobulin-like lectins
(Siglecs). CD33 triggers immune cell–cell interactions
through its own clathrin-independent endocytosis [107]. It
has been shown that CD33 expression is increased in AD
brains [85], as is the number of CD33-positive microglia
[108]. Both affected and asymptomatic carriers of the ‘C’
risk allele for the associated CD33/rs3865444 variant have
a higher probability of being positive for Pittsburgh
Compound B (PiB). Notably, carriers of ‘C’ risk allele also
have a higher likelihood of obtaining an AD diagnosis, but
the effects of the risk allele appear to have no bearing on
tangle formation and are thus limited to plaque pathology,
likely due to its inhibition of Ab42 uptake and clearance by
microglia [108, 109].
CASS4 (Cas Scaffolding Protein Family Member 4)
CASS4 is a relatively understudied gene as evidenced by a
mere three publications returned in a PubMed search for
the gene and its alias, HEPL. The reported GWAS signif-
icant SNP, CASS4/rs7274581, is protective against AD,
and a SNP in LD with this GWAS SNP, CASS4/rs6024870,
shows evidence of regulatory function as well [Rosenthal,
unpublished data]. CASS4 is a member of the CAS protein
family, scaffolding proteins responsible for a number of
cellular activities [110]. First characterized in 2008,
CASS4 shares up to 42 % similarity in gene sequence with
the other three members of the CASS family, but lacks the
conserved YDYVHL motif. It is most highly expressed in
spleen and lung tissues, as well as ovarian and leukemia
cell lines, and its importance appears to be cell-specific and
dependent upon the presence or absence other CAS family
members’ expression [111]. Dcas, the Drosophila homolog
to CAS family proteins, interacts with integrin pathway
genes during early embryogenesis [112], and Kirsch et al.
[113] have also demonstrated an interaction between
another CAS family member, CASS1, and an established
AD locus, CD2AP.
Identification of LOAD Genes by Genomic Sequencing
In addition to APOE, GWAS have made significant con-
tribution in identifying 20 genes/loci for LOAD, but
together common variants in these 21 genes explain about
half of the estimated *80 % heritability of AD [5]. This
finding is consistent with published data for different dis-
eases and traits where GWAS explain only a small fraction
of the estimated genetic variance [114, 115], partly because
GWAS arrays are designed to capture mainly the common
variants with low penetrance and not the rare variants
having higher individual penetrance. In the post-GWAS
era, it is becoming necessary to perform genomic
sequencing (targeted sequencing, whole exome-sequencing
or whole-genome sequencing) in order to detect functional
rare variants not only in known genes, but this approach
will also help to identify new genes for LOAD. Recently,
the application of whole-exome sequencing has resulted in
the identification of rare functional variants in three addi-
tional genes for LOAD, including APP, TREM2 and PLD3.
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APP (Amyloid Precursor Protein)
The association between APP and AD is well established
for EOAD; however, it was not until recently that a link
between APP and the common LOAD was reported. APP
is sequentially cleaved by a-secretase and then c-secretase
to produce amyloid intracellular domain and C3 fragments.
Cleavage of APP by b-secretase rather than a-secretase
produces a longer version of the peptide that is prone to
aggregation and results in the formation of Ab plaques
characteristic of AD. A rare protective variant, A673T, has
been identified in Icelandic and Finnish individuals with a
strong effect size [12, 116]. Thus far, it seems the link
between this rare variant is restricted to members of these
populations as other studies have not detected this variant
in other populations [117, 118]. However, these findings do
suggest that APP may warrant a second look via
sequencing to determine whether other rare variants in this
gene exist that may explain some of the missing heritability
for LOAD.
TREM2 (Triggering Receptor Expressed on Myeloid
Cells 2)
TREM2 has only recently been added to the list of asso-
ciated LOAD genes and stands out among the 24 identified
loci because of a missense mutation that has a similar
effect size to the APOE*E4 allele. The rare R47H variant
was found in both the Icelandic [14•] population and an
international cohort of European descent [13•]. A meta-
analysis of these studies and others reports an odds ratio of
3.4 [119], further strengthening the case for TREM2 as a
major LOAD risk locus. Previously, mutations in TREM2
have been associated with Nasu-Hakola disease (aka
polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy, PLOSL) [120, 121]. This rare
recessive disease counts progressive frontal-type dementia
among its clinical features, which makes the association of
TREM2 with LOAD interesting despite variations in age at
onset and type of dementia [122]. The TREM2 receptor is
expressed by microglia, and expression of its ligands,
TREM2-L, is amplified in apoptotic neurons. Furthermore,
inhibition of TREM2 activity decreases phagocytosis of
these cells by approximately one third, suggesting the
interaction between TREM2 and its ligands facilitates
clearance of apoptotic neurons [123].
PLD3 (Phospholipase D Family, Member 3)
The latest addition to the list of AD risk loci is PLD3. Its
role in LOAD risk was first identified in a small study of 14
families with the variant PLD3/rs145999145 and was val-
idated in a population-based study as increasing LOAD risk
(OR = 2.10). This variant was also associated with age at
onset [15•]. PLD3 is a signaling enzyme about which
little has been described. Zhang et al. [124] have shown
Akt phosphorylation is inhibited in myoblasts when
PLD3 is overexpressed, and Osisami et al. [125] have
suggested its role in myogenesis may be specifically
related to myotube formation. Remarkably, another risk
locus, PTK2B, has been shown to participate in a sig-
naling pathway responsible for Akt activation [126].
PLD3 also has been identified as a potential modifier of
BRCA1 and BRCA2 [127].
Pathway Analysis
Using Ingenuity Pathways Analysis software (version
18030641, Ingenuity Systems, Inc., 2014), we were able to
assess the wide variety of shared functions of these loci.
We examined a total of 27 molecules representing the
GWAS loci (Table 2). Not surprisingly, the most signifi-
cant of these function or disease annotations were LOAD
(p = 2.88E - 21) and AD (p = 2.05E - 15) with 9 and 14
molecules implicated, respectively (Table 3). After
removing annotations with three or fewer molecules, we
were left with a total of 36 nominally significant (p \ 0.05)
groups of genes across a number of categories and function
annotations. Late-onset Alzheimer’s disease and Alzhei-
mer’s disease remained the most significant, followed by
engulfment of cells and leukocytes (p = 1.17E – 06,
p = 1.68E - 06, respectively). Both of these annotations
cite APOE, INPP5D, TREM2, ABCA7 and BINI as mole-
cules involved in these processes, with CR1 and PICALM
included in the broader ‘‘engulfment of cells’’ annotation.
The disease annotation with the most molecules involved is
cancer, with 18 of the 27 genes involved (p = 3.63E-03).
Indeed, of the 36 groups of genes, 14 are related to cancer,
immunity/immunological disease or inflammatory respon-
ses/inflammatory disease (Table 3).
ABCA7, BIN1, INPP5D and TREM2 are jointly
implicated in three forms of phagocytosis, as well as
immune response, suggesting they act in tandem to
modify these specific aspects of AD. Similarly, APOE,
CR1, INPP5D, PTK2B and TREM2 are jointly responsible
for movement of phagocytes and myeloid cells, indicating
another group of closely related genes whose activity
affects the same cellular functions. Smaller groups of
related molecules may better inform about the disease
process than individual gene activities such that the whole
phenotype attributed to genetic background is greater than
the sum of its parts.
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The overlap of molecules among different annotations
is important as it suggests these genes do not act in
isolation, but work in combination so that their actions
with respect to disease risk and pathogenesis are
dependent upon each other. For example, genetic varia-
tion in SORL1 may mediate an inflammatory mechanism
when occurring alongside genetic variation in PTK2B,
but may be more relevant to endocytosis when occurring
with genetic variation in CD2AP. As disease mechanisms
become clearer, it will be necessary to view disease risk
as a function of multiple genetic variants and their
interactions.
Conclusion
Upon review of the literature, it becomes apparent that the
genetic mechanisms implicated in AD are incredibly varied
and widely distributed across biological functions. The
combination of these findings emphasizes the complexity
of the disease and suggests multiple therapeutic targets. It
will also be important to consider both genetic and envi-
ronmental factors when attempting to determine major risk
factors, as gene effect sizes may be modulated by external
factors and vice versa. One particularly curious observation
from this review is the number of genes identified by
GWAS of LOAD that also have known roles in cancer risk,
severity and therapy response. Additionally, incidence
rates of cancer seem to be lower among those affected with
AD compared to the general population, and the same can
be said of cancer survivors with respect to AD incidence
[128]. Ganguli [129] comments on this seemingly inverse
relationship between cancer and AD. Given our results
from the pathway analysis, this supposed relationship
warrants a more deliberate focus in future studies to
accurately assess its legitimacy.
Table 2 LOAD risk loci examined in IPA analysis
Symbol Entrez gene name Location
ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 Plasma membrane
APOE Apolipoprotein E Extracellular space
BIN1 Bridging integrator 1 Nucleus
CASS4 Cas scaffolding protein family member 4 Other
CD2AP CD2-associated protein Cytoplasm
CD33 CD33 molecule Plasma membrane
CELF1 CUGBP, Elav-like family member 1 Nucleus
CLU Clusterin Cytoplasm
CR1 Complement component (3b/4b) receptor 1 (Knops blood group) Plasma membrane
EPHA1 EPH receptor A1 Plasma membrane
FERMT2 Fermitin family member 2 Cytoplasm
HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 Plasma membrane
HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 Plasma membrane
INPP5D Inositol polyphosphate-5-phosphatase, 145 kDa Cytoplasm
MEF2C Myocyte enhancer factor 2C Nucleus
MS4A4A Membrane-spanning 4-domains, subfamily A, member 4A Other
MS4A4E Membrane-spanning 4-domains, subfamily A, member 4E Other
MS4A6A Membrane-spanning 4-domains, subfamily A, member 6A Other
MS4A6E Membrane-spanning 4-domains, subfamily A, member 6E Other
NME8 NME/NM23 family member 8 Cytoplasm
PICALM Phosphatidylinositol binding clathrin assembly protein Cytoplasm
PTK2B Protein tyrosine kinase 2 beta Cytoplasm
RIN3 Ras and Rab interactor 3 Cytoplasm
SLC24A4 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 Plasma membrane
SORL1 Sortilin-related receptor, L(DLR class) A repeats containing Cytoplasm
TREM2 Triggering receptor expressed on myeloid cells 2 Plasma membrane
ZCWPW1 Zinc finger, CW type with PWWP domain 1 Other
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